- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06145555
Estabilización psicológica aguda del sueño para pacientes hospitalizados con depresión
Disturbed sleep occurs in almost all patients in psychiatric inpatient care, and although it is well known that comorbid sleep disorders in depression often persist after treatment of depression and also increase the risk of new depressive episodes, the availability of effective, evidence-based treatments for sleep disorders in hospitalised patients is very limited.
The overall goal of the current project is to translate, adapt and evaluate an acute psychological sleep treatment based on cognitive behavioural therapy for insomnia (CBT-I) for patients hospitalized with depression and comorbid sleep problems in the specialized psychiatric inpatient care in the Stockholm Region. The main hypothesis for the study is that acute psychological sleep stabilization (APS) reduces self-reported sleep complains compared to care as usual reinforced with sleep hygiene advice, and secondary hypotheses are that APS also leads to reduced depressive symptoms and earlier discharge.
The project includes a pilot study, which will be followed by a randomized, controlled trial of APS compared to care as usual with structured sleep hygiene (minimal active control) and treatment effect is evaluated every three days during the hospital stay and 1,2,4 and 12 weeks after randomization. APS will be performed by existing staff in the department with the support of a psychologist.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Stockholm, Suecia
- Psykiatri Sydväst, Karolinska Hospital Huddinge
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Admitted to the psychiatric inpatient care (Psykiatri Sydväst)
- Depressive symptoms / confirmed depressive episode (uni- or bipolar)
- Reports or is observed to have sleep problems in the form of insomnia, hypersomnia or delayed circadian phase
- Knowledge of Swedish or English that is deemed sufficient to undergo the treatment
- Consent to be included in the study and is judged to have understood what the study entails (care according to the Compulsory Psychiatric Care Act is not in itself an exclusion criterion)
Exclusion Criteria:
- Dementia
- Intellectual disability
- Severe somatic comorbidity with life expectancy <6 months
- Ongoing mania / mixed-state
- Complex problems that make APS impossible or inappropriate
- Expected discharge within 3 days
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Acute psychological sleep stabilization
The basis of the treatment is CBT-I adapted to a short version performed by trained staff (nurses or mental health care assistants) together with a psychologist. The manuals are designed to be read by patients and staff together and each treatment manual covers a specific topic. The focus of the treatment is behavioral changes and central manuals are stimulus control and scheduled sleep and sleep compression (if needed). |
See above (arm description) |
|
Comparador activo: Sleep hygiene education
The control treatment is delivered through structured manuals which patients work through together with the staff. The manuals cover sleep hindering factors (eg coffee, nicotine), sleep promoting factors (eg physical activity during the day, relaxation, blinds), sleep aids (for example, weight blanket, calm music). |
See above (arm description) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Insomnia Severity Index
Periodo de tiempo: 2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)
|
A self-report measure of insomnia symptoms. 7-item, self-rated questionnaire measuring insomnia severity. Total score 0-28, higher score indicates more severe sleep problems. |
2 weeks post randomization (secondary timepoints include day 4, 7, 10 and week 4 and 12)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Patient Health Questionnaire (PHQ-9)
Periodo de tiempo: Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
Self-reported depressive symptoms. PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. Total score 0-27, higher score indicates more severe depressive symptoms. |
Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
|
Generalised Anxiety Disorder 7-item scale (GAD-7)
Periodo de tiempo: Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
Self-reported anxiety symptoms. A seven-item instrument that is used to measure or assess the severity of generalised anxiety disorder/symptoms. Total score 0-27. Higher scores indicative of more severe problem. |
Day 4, 7, 10 14 and week 4 and 12 post randomisation
|
|
European Quality of Life 5 Dimensions scale (EQ-5D)
Periodo de tiempo: Week 2, 4 and 12 post randomisation
|
Self-reported quality of life. An instrument which evaluates the generic quality of life developed in Europe and widely used. The scale comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. |
Week 2, 4 and 12 post randomisation
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sleep Diary
Periodo de tiempo: 0-14 days post randomisation
|
Participants will report their bedtime, risetime, amount of sleep daily using a simplified version of a sleep diary. We will look at total sleep time, sleep efficiency, and timing of sleep. |
0-14 days post randomisation
|
|
Actigraphy
Periodo de tiempo: 0-14 days post randomisation
|
An actigraph is placed on the participant's arm for 2 weeks. It measures participants' arm-movements. An algorithm can be used to estimate sleep from movement data.Data from actigraphs will be reported and analysed |
0-14 days post randomisation
|
|
Side effects of treatment
Periodo de tiempo: Day 7 and 14 post randomisation
|
Patients will be asked to report any side-effects of the treatment with an open question |
Day 7 and 14 post randomisation
|
|
Treatment Credibility Scale
Periodo de tiempo: Day 4 post randomisation
|
A five-item version of Credibility/Expectancy Questionnaire, total score ranging from 0-50. Higher scores indicative of higher credibility. |
Day 4 post randomisation
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Sandra Tamm, Karolinska Institutet
- Investigador principal: Susanna Jernelöv, Karolinska Institutet
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Dnr 2023-02223-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual data will not be shared
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .